Sertraline: a new specific serotonin reuptake blocker.
Sertraline hydrochloride is a new naphthylamino compound that specifically blocks neuronal reuptake of serotonin. It is currently available in the United Kingdom and under review in the US. Sertraline follows first-order kinetics, with a plasma elimination half-life of 24-26 hours. It is highly bound to plasma proteins and has a large volume of distribution. Multicenter studies conducted by the manufacturer have shown sertraline to be efficacious in the treatment of depression and obsessive-compulsive disorder. The daily dose will range from 50 to 200 mg/d for the treatment of depression. The adverse-effect profile differs greatly from the tricyclic antidepressants, but is similar to that of fluoxetine. The most prominent adverse effects are gastrointestinal (nausea, diarrhea/loose stools, dyspepsia).
Guthrie
S K
SK
College of Pharmacy, University of Michigan, Ann Arbor 48109.
D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D000368:Aged; D000428:Alcohol Drinking / Q000188:drug therapy; D000818:Animals; D001066:Appetite / Q000187:drug effects; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D015536:Down-Regulation / Q000187:drug effects; D004347:Drug Interactions; D006801:Humans; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D011597:Psychomotor Performance / Q000187:drug effects; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D020280:Sertraline
D012702:Serotonin Antagonists; D015057:1-Naphthylamine; D020280:Sertraline